CW January 2002
Volume 11Issue Number 1 January 2002 ISSN 10593802 Campath Effective in Front-Line and Refractory B-CLLClinical studies presented at the American Society of Hematology 43rd Annual Meeting and Exposition demonstrated impressive results for subcutaneous Campath? 1-H (alemtuzumab) in patients with B-cell chronic lymphocytic leukemia. Separate studies looked at previously untreated patients as well as refractory ones failing prior regimens.
Go to Previous Page Go to Next Page Source & Additional Reading 43rd Annual Meeting of American Society of Hematology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
